Under the collaboration, GSK integrates its expertise in medicinal chemistry with Yale’s work on proteolysis targeting chimeric molecules (PROTACs).
The PROTAC technology directs disease-causing proteins to a cell’s garbage disposal where they can be destroyed.
Yale will be eligible for milestone and royalty payments for each protein-degrading drug that is discovered and developed, as per the agreement.
GSK Protein Degradation effort head Kris Famm said, "This partnership is exploring a new way for promising, but unproven therapeutic approaches to jump from the academic lab more quickly into the early stage pharmaceutical pipeline,"